[{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"701c790f-d71e-4882-8490-72c4deac7a2f","acronym":"BYON3521.001","url":"https://clinicaltrials.gov/study/NCT05323045","created_at":"2022-04-12T14:52:58.036Z","updated_at":"2024-07-02T16:34:37.322Z","phase":"Phase 1","brief_title":"A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521","source_id_and_acronym":"NCT05323045 - BYON3521.001","lead_sponsor":"Byondis B.V.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BYON3521"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"13166d68-2e61-4c72-92f1-fac024df7835","acronym":"SAFFRON","url":"https://clinicaltrials.gov/study/NCT05261399","created_at":"2022-03-02T17:52:38.442Z","updated_at":"2024-07-02T16:34:59.035Z","phase":"Phase 3","brief_title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","source_id_and_acronym":"NCT05261399 - SAFFRON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/26/2025","primary_completion_date":" 06/26/2025","study_txt":" Completion: 12/17/2026","study_completion_date":" 12/17/2026","last_update_posted":"2024-06-04"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"},{"id":"ef2ab7b8-a2e5-4df2-83fe-3e4e96f58f67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04693468","created_at":"2021-01-19T20:49:06.628Z","updated_at":"2024-07-02T16:34:58.952Z","phase":"Phase 1","brief_title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","source_id_and_acronym":"NCT04693468","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • ALK translocation","tags":["ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/03/2025","primary_completion_date":" 09/03/2025","study_txt":" Completion: 09/03/2025","study_completion_date":" 09/03/2025","last_update_posted":"2024-06-04"},{"id":"bda81f7a-e7db-4896-93fc-dd002a685704","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101356","created_at":"2023-10-12T19:12:04.905Z","updated_at":"2024-07-02T16:35:02.238Z","phase":"Phase 1/2","brief_title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","source_id_and_acronym":"NCT05101356","lead_sponsor":"Tianhong Li","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • MET mutation","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-21"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"e3cb8ff7-aee3-44ab-9a12-a32ca7fbea3e","acronym":"GeoMETry-C","url":"https://clinicaltrials.gov/study/NCT04677595","created_at":"2021-01-19T20:46:00.824Z","updated_at":"2024-07-02T16:35:04.004Z","phase":"Phase 2","brief_title":"Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","source_id_and_acronym":"NCT04677595 - GeoMETry-C","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/17/2021","start_date":" 05/17/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-14"},{"id":"7bef29a7-07ed-4332-9706-9ee664c0f131","acronym":"Lung-MAP Non-Match Sub-Study","url":"https://clinicaltrials.gov/study/NCT05096663","created_at":"2021-10-27T14:53:21.327Z","updated_at":"2024-07-02T16:35:05.962Z","phase":"Phase 2/3","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05096663 - Lung-MAP Non-Match Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-03"},{"id":"677edd33-9a1c-430c-98a8-3977cf1e241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110196","created_at":"2021-11-05T12:53:26.883Z","updated_at":"2024-07-02T16:35:07.074Z","phase":"Phase 4","brief_title":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","source_id_and_acronym":"NCT05110196","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK • MET","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation","tags":["EGFR • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2022","start_date":" 09/03/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-04-29"},{"id":"2af63127-3115-4ddf-9da7-0032fefe8e92","acronym":"iPREDICT","url":"https://clinicaltrials.gov/study/NCT05013099","created_at":"2021-08-19T14:52:55.130Z","updated_at":"2024-07-02T16:35:10.176Z","phase":"Phase 2","brief_title":"Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies","source_id_and_acronym":"NCT05013099 - iPREDICT","lead_sponsor":"ImaginAb, Inc.","biomarkers":" PD-L1 • KRAS • CD8 • PD-1","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression","tags":["PD-L1 • KRAS • CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-11"},{"id":"a4db82ac-25ea-4169-8bb8-cb613afd0358","acronym":"ATATcH","url":"https://clinicaltrials.gov/study/NCT05358548","created_at":"2022-05-03T14:53:59.407Z","updated_at":"2024-07-02T16:35:10.415Z","phase":"Phase 2","brief_title":"ATATcH Alternating Treatment Plans for Advanced Cancer","source_id_and_acronym":"NCT05358548 - ATATcH","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"40df6160-751e-485f-9648-832a744ed37a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077099","created_at":"2021-01-18T19:58:00.182Z","updated_at":"2024-07-02T16:35:16.114Z","phase":"Phase 1/2","brief_title":"REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04077099","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e davutamig (REGN5093)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 10/20/2024","study_completion_date":" 10/20/2024","last_update_posted":"2024-03-06"},{"id":"ba256708-bd68-4aa8-a289-341634b3901f","acronym":"SOUND","url":"https://clinicaltrials.gov/study/NCT05374603","created_at":"2022-05-16T13:53:43.301Z","updated_at":"2024-07-02T16:35:16.700Z","phase":"Phase 2","brief_title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05374603 - SOUND","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Orpathys (savolitinib)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"e04f5494-d279-4e73-86ac-66647b597c64","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757492","created_at":"2023-03-07T18:02:53.388Z","updated_at":"2024-07-02T16:35:18.481Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05757492","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • MET mutation • ROS1 mutation","tags":["EGFR • PD-L1 • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • MET mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • JS006"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 04/26/2023","start_date":" 04/26/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-20"},{"id":"342a7365-a0cb-40b4-a3bd-26c53a69ba15","acronym":"INHERIT","url":"https://clinicaltrials.gov/study/NCT05587439","created_at":"2022-10-20T14:11:35.154Z","updated_at":"2024-07-02T16:35:18.802Z","phase":"","brief_title":"Investigating Hereditary Risk In Thoracic Cancers (INHERIT)","source_id_and_acronym":"NCT05587439 - INHERIT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR • HER-2 • YAP1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • MET mutation • EGFR R776H","tags":["EGFR • HER-2 • YAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • MET mutation • EGFR R776H"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-02-19"},{"id":"d047ec17-efa7-4564-abbc-fb67b11e702a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05312398","created_at":"2022-04-05T13:52:46.554Z","updated_at":"2024-07-02T16:35:21.243Z","phase":"Phase 2","brief_title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","source_id_and_acronym":"NCT05312398","lead_sponsor":"University of Campania \"Luigi Vanvitelli\"","biomarkers":" HER-2 • BRAF • MET • PTEN • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • MET amplification • BRAF wild-type • RAS mutation • MET mutation","tags":["HER-2 • BRAF • MET • PTEN • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • MET amplification • BRAF wild-type • RAS mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 06/15/2026","study_completion_date":" 06/15/2026","last_update_posted":"2024-02-01"},{"id":"cc6784ad-5408-45ec-a940-e7803eaea6ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777175","created_at":"2021-03-02T12:52:17.480Z","updated_at":"2024-07-02T16:35:25.196Z","phase":"","brief_title":"A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04777175","lead_sponsor":"Yongchang Zhang","biomarkers":" HER-2 • BRAF • ALK","pipe":" | ","alterations":" BRAF mutation • HER-2 mutation • ALK mutation • RET mutation • MET mutation","tags":["HER-2 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 mutation • ALK mutation • RET mutation • MET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/12/2025","study_completion_date":" 01/12/2025","last_update_posted":"2023-12-27"},{"id":"5d9a2d22-a701-4304-82b2-d07cf3b47eb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01723774","created_at":"2021-01-18T07:31:32.711Z","updated_at":"2024-07-02T16:35:25.670Z","phase":"Phase 2","brief_title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","source_id_and_acronym":"NCT01723774","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation • MET mutation • PIK3CA wild-type","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation • MET mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • anastrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 04/10/2013","start_date":" 04/10/2013","primary_txt":" Primary completion: 04/13/2021","primary_completion_date":" 04/13/2021","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2023-12-20"},{"id":"db94dab1-91ab-404b-ac8a-f0cbedaa2ba2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04311034","created_at":"2021-01-18T20:54:00.404Z","updated_at":"2024-07-02T16:35:25.956Z","phase":"Phase 1/2","brief_title":"A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04311034","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/26/2018","start_date":" 09/26/2018","primary_txt":" Primary completion: 12/21/2021","primary_completion_date":" 12/21/2021","study_txt":" Completion: 05/30/2022","study_completion_date":" 05/30/2022","last_update_posted":"2023-12-18"},{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"},{"id":"a563cbb8-fb97-4cc4-bda2-54204ed92285","acronym":"Geometry-N","url":"https://clinicaltrials.gov/study/NCT04926831","created_at":"2021-06-15T17:53:18.896Z","updated_at":"2024-07-02T16:35:26.249Z","phase":"Phase 2","brief_title":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC","source_id_and_acronym":"NCT04926831 - Geometry-N","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 08/10/2022","start_date":" 08/10/2022","primary_txt":" Primary completion: 08/06/2026","primary_completion_date":" 08/06/2026","study_txt":" Completion: 08/06/2026","study_completion_date":" 08/06/2026","last_update_posted":"2023-12-14"}]